WCM
XERS icon

WealthTrak Capital Management’s Xeris Biopharma Holdings XERS Stock Holding History

WealthTrak Capital Management’s Portfolio XERS Stock Details XERS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		– Sell
-40
Closed -$187 – 898
2025
Q2 		$187 Hold
40
– – ﹤0.01% 845
2025
Q1 		$220 Hold
40
– – ﹤0.01% 836
2024
Q4 		$136 Buy
+40
New +$129 ﹤0.01% 854

Other funds holding XERS

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Qube Research & Technologies (QRT)
Qube Research & Technologies (QRT) London, United Kingdom $89.9B AUM 20.22% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
N
Nuveen Charlotte, North Carolina $369B AUM 31.66% 1-Year Est. Return
DCM
Driehaus Capital Management Chicago, Illinois $13.6B AUM 173.98% 1-Year Est. Return
RA
Rosalind Advisors Toronto, Ontario, Canada $249M AUM 80.12% 1-Year Est. Return

WealthTrak Capital Management's XERS Position: Q3 2025 in Review

WealthTrak Capital Management sold out of Xeris Biopharma Holdings (XERS) in Q3 2025, closing a stake of 40 shares — an estimated $187 sold.

WealthTrak Capital Management first reported a position in XERS in Q4 2024 and held it in 3 quarters. The position peaked at $220 in Q1 2025. 230 funds tracked by Wall St. Rank hold XERS as of Q3 2025.

  • WealthTrak Capital Management reported no remaining Xeris Biopharma Holdings position as of Q3 2025 after selling out during the quarter.
  • WealthTrak Capital Management sold 40 Xeris Biopharma Holdings shares in Q3 2025, an estimated $187.
  • WealthTrak Capital Management first reported a position in Xeris Biopharma Holdings in Q4 2024 and held it in 3 quarters.
  • WealthTrak Capital Management's Xeris Biopharma Holdings position peaked at $220 in Q1 2025.
  • 230 funds tracked by Wall St. Rank held Xeris Biopharma Holdings as of Q3 2025.

Based on WealthTrak Capital Management's 13F filing for Q3 2025, filed 14 Nov 2025.